Elicio Therapeutics Inc.
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Elicio Therapeutics Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 1.80 $ to 14.90 $ · Last price: 1.90 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Elicio Therapeutics Inc. ELTX | 0.0 | – | -2.6 | – | – | -100.0 | -83.8 |
| Vertex Pharmaceuticals Inc VRTX | 130.6 | 31.3 | 24.5 | 55.0 | 38.1 | 9.6 | 33.4 |
| Regeneron Pharmaceuticals Inc REGN | 82.0 | 19.9 | 13.1 | 44.5 | 20.7 | 1.0 | 35.5 |
| Moderna Inc MRNA | 62.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| argenx NV ARGX | 61.9 | 38.1 | 34.2 | 59.1 | 32.0 | 89.6 | 30.9 |
| Revolution Medicines Inc RVMD | 40.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 338.3 |
| BeiGene, Ltd. ONC | 40.0 | 63.1 | 34.1 | 88.9 | 19.1 | 40.2 | 6.4 |
| Alnylam Pharmaceuticals Inc ALNY | 32.6 | 61.8 | 28.4 | 79.7 | 23.0 | 65.2 | -48.1 |
| Royalty Pharma Plc RPRX | 32.5 | 31.8 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Median of companies shown | 40.9 | 34.9 | 19.6 | 57.0 | 21.8 | 5.1 | 33.4 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2012 | 7 | 0 | 0 | 50.21 | 1 | 2 | 11 |
| 2013 | 7 | 0 | 1 | 103.31 | 2 | 2 | 11 |
| 2018 | 4 | -14 | -20 | -6.79 | -8 | 19 | 27 |
| 2019 | 1 | -39 | -41 | -4.99 | -25 | -19 | 12 |
| 2020 | 3 | -55 | -80 | -9.83 | -23 | -90 | 47 |
| 2021 | 28 | -39 | -26 | -8.25 | -24 | 82 | 97 |
| 2022 | 0 | -24 | -28 | -9.10 | -22 | 9 | 23 |
| 2023 | 0 | -36 | -35 | -6.96 | -33 | 11 | 27 |
| 2024 | 0 | -45 | -52 | -4.25 | -37 | -11 | 28 |
| 2025 | 0 | -38 | -40 | -2.58 | -37 | 2 | 26 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.02 | – | 1 | – | -1,201.00 | -9 | -9 |
| 2025: Q1 | -0.87 | – | 0 | – | – | -10 | -10 |
| 2025: Q2 | -0.66 | – | 0 | – | – | -9 | -9 |
| 2025: Q3 | -0.60 | – | 0 | – | – | -11 | -11 |
| 2025: Q4 | -0.49 | – | 0 | -100.00 | – | -7 | -7 |
| 2026: Q1 | -0.65 | – | 0 | – | – | -12 | -12 |
| 2026: Q2 | -0.43 | 34.80 | – | – | – | -8 | -8 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Momentum & Trend
Risk & Weakness
- Bankruptcy Study: Stacked Warning Signals
- Below the 50- & 200-SMA
- Going Concern (Distress Proxy)
- Insolvency Radar: Cash Running Low
- RS Weakness (≤10)
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.95 | -2.17 – -1.83 | 0 | 24.4% | 3 |
| 12/31/2027 | -2.17 | -3.00 – -1.38 | 0 | -11.0% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 0.0%
- Share count grows by less than 3% a year 70.3%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 4 m net cash
- Operating cash flow covers the profits of the last three years 20 m
- Return on capital at 15% or higher, or up versus two years ago -212.5%
- Insiders hold at least 10% or are net buyers 29.8%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -100.0%
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight –
- Max. EBIT decline < 50% –
- Return on equity > 15% -2,418.7%
- ROCE > 15% -212.4%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
Elicio Therapeutics, Inc., ein Biotechnologieunternehmen in der klinischen Phase, entwickelt Immuntherapien zur Krebsbehandlung.
- Employees
- 33
- Headquarters
- Boston, MA
- Address
- 451 D Street, 02210 Boston, United States
- Phone
- 857 209 0050
- Website
- elicio.com
- IPO Date
- 02/05/2021
- ISIN
- US28657F1030
- Stock Split
- 1:10 on 06/02/2023
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert T. Connelly | CEO, President & Director | 1960 |
| Allen Richard Nissenson F.A.S.N., FACP, M.D. | Founder & Independent Director | 1947 |
| Preetam Shah M.B.A., Ph.D. | Chief Strategy & Financial Officer and Treasurer | 1973 |
| Christopher M. Haqq M.D., Ph.D. | Executive VP, Head of Research & Development and Chief Medical Officer | 1966 |
| Darrell J. Irvine Ph.D. | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board | – |
| Marc J. Wolfgang M.S. | Chief Technology Officer | – |
| Peter DeMuth Ph.D. | Chief Scientific Officer | 1987 |
| Megan C. Filoon | General Counsel, Secretary & Compliance Officer | – |
| Esther Welkowsky | Senior Vice President of Clinical Development | – |
| Joy Seymour | Senior VP & Head of Regulatory Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.